ECSP21022719A - Formas cristalinas de un inhibidor de fosfoinositida 3quinasa (pi3k) - Google Patents
Formas cristalinas de un inhibidor de fosfoinositida 3quinasa (pi3k)Info
- Publication number
- ECSP21022719A ECSP21022719A ECSENADI202122719A ECDI202122719A ECSP21022719A EC SP21022719 A ECSP21022719 A EC SP21022719A EC SENADI202122719 A ECSENADI202122719 A EC SENADI202122719A EC DI202122719 A ECDI202122719 A EC DI202122719A EC SP21022719 A ECSP21022719 A EC SP21022719A
- Authority
- EC
- Ecuador
- Prior art keywords
- crystalline forms
- pi3k
- phosphoinositide
- kinase inhibitor
- imidazo
- Prior art date
Links
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title abstract 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 2
- 102000038030 PI3Ks Human genes 0.000 title 1
- 108091007960 PI3Ks Proteins 0.000 title 1
- VHMODILVAAVUJY-UHFFFAOYSA-N 8-amino-N-(2-hydroxy-2-methylpropyl)-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound NC=1C=2N(C=C(N=1)C(=O)NCC(C)(C)O)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C)O)C VHMODILVAAVUJY-UHFFFAOYSA-N 0.000 abstract 2
- AIJMGQDXUVKDIN-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxypropanamide Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(=O)N)(C(F)(F)F)O AIJMGQDXUVKDIN-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862727339P | 2018-09-05 | 2018-09-05 | |
US201862727321P | 2018-09-05 | 2018-09-05 | |
US201862727328P | 2018-09-05 | 2018-09-05 | |
US201862746928P | 2018-10-17 | 2018-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21022719A true ECSP21022719A (es) | 2021-06-30 |
Family
ID=69642051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202122719A ECSP21022719A (es) | 2018-09-05 | 2021-03-31 | Formas cristalinas de un inhibidor de fosfoinositida 3quinasa (pi3k) |
Country Status (25)
Country | Link |
---|---|
US (2) | US11186580B2 (sr) |
EP (2) | EP3847175B1 (sr) |
JP (1) | JP2021535182A (sr) |
KR (1) | KR20210091121A (sr) |
CN (1) | CN113677683A (sr) |
AU (1) | AU2019336675A1 (sr) |
BR (1) | BR112021004094A2 (sr) |
CA (1) | CA3111629A1 (sr) |
CL (1) | CL2021000539A1 (sr) |
CO (1) | CO2021004061A2 (sr) |
CR (1) | CR20210165A (sr) |
DK (1) | DK3847175T3 (sr) |
EC (1) | ECSP21022719A (sr) |
FI (1) | FI3847175T3 (sr) |
HR (1) | HRP20240252T1 (sr) |
IL (2) | IL309869A (sr) |
LT (1) | LT3847175T (sr) |
MA (1) | MA53561A (sr) |
MX (1) | MX2021002551A (sr) |
PE (1) | PE20211815A1 (sr) |
PH (1) | PH12021550472A1 (sr) |
PT (1) | PT3847175T (sr) |
RS (1) | RS65334B1 (sr) |
SG (1) | SG11202102224UA (sr) |
WO (1) | WO2020051169A1 (sr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62818B1 (sr) | 2017-10-18 | 2022-02-28 | Incyte Corp | Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
WO2003035065A1 (en) | 2001-10-26 | 2003-05-01 | Aventis Pharmaceuticals Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
WO2004078943A2 (en) | 2003-03-04 | 2004-09-16 | California Institute Of Technology | Alternative heterocycles for dna recognition |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7511145B2 (en) | 2003-08-01 | 2009-03-31 | Genelabs Technologies, Inc. | Bicyclic heteroaryl derivatives |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
US7745437B2 (en) | 2004-06-10 | 2010-06-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP2008520612A (ja) | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ |
WO2007019344A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds |
EP1928237A4 (en) * | 2005-09-02 | 2011-03-09 | Abbott Lab | NEW HETEROCYCLES BASED ON IMIDAZO |
CA2654358A1 (en) | 2006-06-22 | 2007-12-27 | Biovitrum Ab (Publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
EP2139474A2 (en) | 2007-03-27 | 2010-01-06 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
US8309718B2 (en) | 2007-11-16 | 2012-11-13 | Incyte Corporation | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
EP2234486A4 (en) | 2007-12-19 | 2011-09-14 | Scripps Research Inst | BENZIMIDAZOLE AND ANALOGUE AS RHO-KINASEHEMMER |
CN101990434B (zh) | 2008-01-15 | 2013-07-31 | 西佳技术公司 | 用于治疗沙粒病毒感染的抗病毒药物 |
US8329697B2 (en) | 2008-02-26 | 2012-12-11 | Merck Sharp & Dohme Corp. | Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
WO2009158118A2 (en) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
EP2358202B1 (en) | 2008-11-03 | 2016-06-15 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
WO2010061903A1 (ja) | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体 |
GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
CA2753560A1 (en) | 2009-02-27 | 2010-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションIncyte Corporation | ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体 |
PL2448938T3 (pl) | 2009-06-29 | 2014-11-28 | Incyte Holdings Corp | Pirymidynony jako inhibitory PI3K |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
AR079529A1 (es) | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
AR081315A1 (es) | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
WO2011123609A1 (en) | 2010-03-31 | 2011-10-06 | Glaxo Group Limited | Imidazolyl-imidazoles as kinase inhibitors |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
WO2011149874A2 (en) | 2010-05-26 | 2011-12-01 | Schering Corporation | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
PE20141044A1 (es) | 2010-10-13 | 2014-09-07 | Millennium Pharm Inc | Heteroarilos y sus usos |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
AR084032A1 (es) | 2010-11-30 | 2013-04-17 | Takeda Pharmaceutical | Compuesto biciclico |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
KR20140093610A (ko) | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
PE20140832A1 (es) | 2011-06-20 | 2014-07-14 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
KR102131612B1 (ko) | 2011-09-02 | 2020-07-08 | 인사이트 홀딩스 코포레이션 | Pi3k 억제제로서 헤테로시클릴아민 |
WO2013104610A1 (en) | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines as akt kinase inhibitors |
US9212169B2 (en) | 2012-03-01 | 2015-12-15 | Hyogo College Of Medicine | Benzimidazole derivative and use thereof |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
WO2013180193A1 (ja) | 2012-05-31 | 2013-12-05 | 住友化学株式会社 | 縮合複素環化合物 |
WO2014009295A1 (en) | 2012-07-13 | 2014-01-16 | Ucb Pharma S.A. | Imidazopyridine derivatives as modulators of tnf activity |
SG11201503141TA (en) | 2012-11-01 | 2015-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
TW202214254A (zh) * | 2013-03-01 | 2022-04-16 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
WO2014149207A2 (en) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Benzimidazole-based insecticidal compositions and related methods |
US9656994B2 (en) | 2013-03-22 | 2017-05-23 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
US9394254B2 (en) | 2013-05-08 | 2016-07-19 | The University of Denver and Regis University | Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase |
PE20200527A1 (es) | 2013-05-17 | 2020-03-09 | Incyte Corp | Derivados del bipirazol como inhibidores jak |
SG11201600108PA (en) | 2013-07-17 | 2016-02-26 | Otsuka Pharma Co Ltd | Cyanotriazole compounds |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
HUE051625T2 (hu) | 2014-04-08 | 2021-03-29 | Incyte Corp | B-sejtes rosszindulatú daganatok kezelése JAK és PI3K inhibitorok kombinációjával |
EP2930048A1 (en) | 2014-04-10 | 2015-10-14 | Johnson Controls Automotive Electronics SAS | Head up display projecting visual information onto a screen |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
SG11201702108PA (en) | 2014-09-16 | 2017-04-27 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
US10214537B2 (en) | 2014-10-22 | 2019-02-26 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds |
MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
MD3371190T2 (ro) | 2015-11-06 | 2022-09-30 | Incyte Corp | Compuși heterociclici ca inhibitori PI3K-gamma |
TW201734003A (zh) | 2016-01-05 | 2017-10-01 | 英塞特公司 | 作為PI3K-γ抑制劑之吡啶及嘧啶化合物 |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
EP3505171A4 (en) | 2016-08-26 | 2020-08-26 | Mitsubishi Tanabe Pharma Corporation | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND |
RS62818B1 (sr) * | 2017-10-18 | 2022-02-28 | Incyte Corp | Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma |
-
2019
- 2019-09-04 SG SG11202102224UA patent/SG11202102224UA/en unknown
- 2019-09-04 DK DK19858443.5T patent/DK3847175T3/da active
- 2019-09-04 CN CN201980071241.6A patent/CN113677683A/zh active Pending
- 2019-09-04 PT PT198584435T patent/PT3847175T/pt unknown
- 2019-09-04 CR CR20210165A patent/CR20210165A/es unknown
- 2019-09-04 WO PCT/US2019/049419 patent/WO2020051169A1/en active Application Filing
- 2019-09-04 BR BR112021004094-3A patent/BR112021004094A2/pt unknown
- 2019-09-04 RS RS20240361A patent/RS65334B1/sr unknown
- 2019-09-04 EP EP19858443.5A patent/EP3847175B1/en active Active
- 2019-09-04 PE PE2021000289A patent/PE20211815A1/es unknown
- 2019-09-04 US US16/560,087 patent/US11186580B2/en active Active
- 2019-09-04 AU AU2019336675A patent/AU2019336675A1/en active Pending
- 2019-09-04 MA MA053561A patent/MA53561A/fr unknown
- 2019-09-04 CA CA3111629A patent/CA3111629A1/en active Pending
- 2019-09-04 LT LTEPPCT/US2019/049419T patent/LT3847175T/lt unknown
- 2019-09-04 FI FIEP19858443.5T patent/FI3847175T3/fi active
- 2019-09-04 IL IL309869A patent/IL309869A/en unknown
- 2019-09-04 MX MX2021002551A patent/MX2021002551A/es unknown
- 2019-09-04 JP JP2021512576A patent/JP2021535182A/ja active Pending
- 2019-09-04 EP EP24153948.5A patent/EP4338801A3/en active Pending
- 2019-09-04 KR KR1020217009964A patent/KR20210091121A/ko unknown
- 2019-09-04 HR HRP20240252TT patent/HRP20240252T1/hr unknown
-
2021
- 2021-03-04 IL IL281262A patent/IL281262A/en unknown
- 2021-03-04 CL CL2021000539A patent/CL2021000539A1/es unknown
- 2021-03-05 PH PH12021550472A patent/PH12021550472A1/en unknown
- 2021-03-31 CO CONC2021/0004061A patent/CO2021004061A2/es unknown
- 2021-03-31 EC ECSENADI202122719A patent/ECSP21022719A/es unknown
- 2021-10-27 US US17/452,507 patent/US20220112198A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DK3847175T3 (da) | 2024-03-18 |
US20200071335A1 (en) | 2020-03-05 |
EP4338801A3 (en) | 2024-06-05 |
AU2019336675A1 (en) | 2021-03-25 |
EP3847175A4 (en) | 2022-05-11 |
IL309869A (en) | 2024-02-01 |
CN113677683A (zh) | 2021-11-19 |
PH12021550472A1 (en) | 2021-11-22 |
US11186580B2 (en) | 2021-11-30 |
TW202024088A (zh) | 2020-07-01 |
CR20210165A (es) | 2021-10-01 |
US20220112198A1 (en) | 2022-04-14 |
MX2021002551A (es) | 2021-07-15 |
SG11202102224UA (en) | 2021-04-29 |
FI3847175T3 (fi) | 2024-03-22 |
MA53561A (fr) | 2022-05-11 |
LT3847175T (lt) | 2024-03-25 |
HRP20240252T1 (hr) | 2024-05-24 |
BR112021004094A2 (pt) | 2021-05-25 |
CA3111629A1 (en) | 2020-03-12 |
KR20210091121A (ko) | 2021-07-21 |
JP2021535182A (ja) | 2021-12-16 |
WO2020051169A1 (en) | 2020-03-12 |
EP3847175A1 (en) | 2021-07-14 |
EP3847175B1 (en) | 2024-02-07 |
CL2021000539A1 (es) | 2021-08-20 |
CO2021004061A2 (es) | 2021-06-10 |
IL281262A (en) | 2021-04-29 |
EP4338801A2 (en) | 2024-03-20 |
RS65334B1 (sr) | 2024-04-30 |
PE20211815A1 (es) | 2021-09-14 |
PT3847175T (pt) | 2024-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003188A1 (es) | Sales de inhibidor de pi3k y procesos de preparación. (divisional solicitud 201702179) | |
MX2020003552A (es) | Formas cristalinas. | |
PE20191499A1 (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
CU20210015A7 (es) | COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
JO3279B1 (ar) | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز | |
BR112014018528A8 (pt) | Derivados de pirido [2,3] pirimidina 2-amino, 6-fenil substituídos úteis como inibidores de raf quinase | |
UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
CR11151A (es) | Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-ciclopentilpropanitrilo | |
AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
CO2020005009A2 (es) | Sales de derivados de pirrolotriazina útiles como inhibidores de tam | |
PE20160529A1 (es) | Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas | |
MX2018004332A (es) | Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas. | |
AR074379A1 (es) | Inhibidor de triazolotiadiazola de la proteina quinasa c-met | |
ECSP10010389A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
ECSP10010392A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
DK3083627T3 (da) | [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis | |
DOP2023000145A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
ECSP21022719A (es) | Formas cristalinas de un inhibidor de fosfoinositida 3quinasa (pi3k) | |
MX2020004148A (es) | Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf). | |
BR112018076622A2 (pt) | pirrolo[2,3-d]piridazin-4-onas e pirazolo[3,4-d]piridazin-4-onas substituídas como inibidores de proteína cinase | |
CO2021004130A2 (es) | Método mejorado para la fabricación de 3-[(1s)-1-imidazo[1,2-a]piridin-6-iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimórficas de la misma | |
AR116119A1 (es) | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) | |
CL2022002205A1 (es) | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) (div. sol. 202100539). | |
CL2022002204A1 (es) | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) (div. sol. 202100539). |